FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Beck

Research Profile

Physiology

Anatomy

Chemicals & Drugs

Disorders

Leukemia

Co-author Network

Publications

TOP 3
Ahmet D Arslan; Xiaolong He; Lijun Rong; Emily Rumschlag-Booms; Minxiu Wang; William T Beck
A high-throughput assay to identify small-molecule modulators of alternative pre-mRNA splicing.
Sungpil Cho; Lucio Miele; Meiling Lu; Pui-Lai Rachel Ee; Erasmus Schneider; Xiaolong He; Uppoor G Bhat; William T Beck
Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells.
Sonia G Das; Jignesh M Doshi; David L Hermanson; Balasubramanian Srinivasan; Ruoping Tang; William T Beck; Nicholas P Bleeker; Chengguo Xing
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Beck (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ahmet D Arslan; Xiaolong He; Lijun Rong; Emily Rumschlag-Booms; Minxiu Wang; William T Beck
A high-throughput assay to identify small-molecule modulators of alternative pre-mRNA splicing.
Journal of biomolecular screening 2013;18(2):180-90.
2011: Sungpil Cho; Lucio Miele; Meiling Lu; Pui-Lai Rachel Ee; Erasmus Schneider; Xiaolong He; Uppoor G Bhat; William T Beck
Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(51):20778-83.
2011: Sonia G Das; Jignesh M Doshi; David L Hermanson; Balasubramanian Srinivasan; Ruoping Tang; William T Beck; Nicholas P Bleeker; Chengguo Xing
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
Journal of medicinal chemistry 2011;54(16):5937-48.
2011: Karthika Natarajan; Kenneth S. Bauer; William T Beck; Takeo Nakanishi; Yi Xie; Douglas Ross
Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine.
Biochimica et biophysica acta 2011;1809(7):295-305.
2011: Cheng-Fen Chen; Xiaolong He; Ahmet Dirim Arslan; Yin-Yuan Mo; William C Reinhold; Yves Pommier; William T Beck
Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.
Molecular pharmacology 2011;79(4):735-41.
2011: Xiaolong He; Ahmet D Arslan; M D Pool; T-T Ho; K M Darcy; John S Coon; William T Beck
Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer.
Oncogene 2011;30(3):356-65.
2009: Fei Shen; Barbara J Bailey; Shaoyou Chu; Aimee K Bence; Xinjian Xue; Priscilla Erickson; Ahmad R Safa; William T Beck; Leonard C Erickson
Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.
The Journal of pharmacology and experimental therapeutics 2009;330(2):423-9.
2009: Fangting Wu; Shuomin Zhu; Yanna Ding; William T Beck; Yin-Yuan Mo
MicroRNA-mediated regulation of Ubc9 expression in cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1550-7.
2008: Fei Shen; Shaoyou Chu; Aimee K Bence; Barbara Bailey; Xinjian Xue; Priscilla A Erickson; Marshall H Montrose; William T Beck; Leonard C Erickson
Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.
The Journal of pharmacology and experimental therapeutics 2008;324(1):95-102.
2007: Xiaolong He; M Pool; K M Darcy; Sok Bee Lim; N Auersperg; John S Coon; William T Beck
Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro.
Oncogene 2007;26(34):4961-8.
2007: Fangting Wu; Susanna Chiocca; William T Beck; Yin-Yuan Mo
Gam1-associated alterations of drug responsiveness through activation of apoptosis.
Molecular cancer therapeutics 2007;6(6):1823-30.
2007: Shelagh E L Mirski; Kathryn E Sparks; Beate Friedrich; Matthias Köhler; Yin-Yuan Mo; William T Beck; SUSAN COLE
Topoisomerase II binds importin alpha isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells.
Experimental cell research 2007;313(3):627-37.
2005: Sitharthan Kamalakaran; Senthil K Radhakrishnan; William T Beck
Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites.
The Journal of biological chemistry 2005;280(22):21491-7.
2005: Yin-Yuan Mo; Yanni Yu; Elena Theodosiou; P L Rachel Ee; William T Beck
A role for Ubc9 in tumorigenesis.
Oncogene 2005;24(16):2677-83.
2004: Pui Lai Rachel Ee; Xiaolong He; Douglas Ross; William T Beck
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Molecular cancer therapeutics 2004;3(12):1577-83.
2004: Xiaolong He; Pui Lai Rachel Ee; John S Coon; William T Beck
Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4652-60.
2004: Yin-Yuan Mo; Yanni Yu; Pui Lai Rachel Ee; William T Beck
Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs.
Cancer research 2004;64(8):2793-8.
2004: Pui Lai Rachel Ee; Sitharthan Kamalakaran; Debra A Tonetti; Xiaolong He; Douglas Ross; William T Beck
Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.
Cancer research 2004;64(4):1247-51.
2002: Prasad Rallabhandi; Keiko Hashimoto; Yin-Yuan Mo; William T Beck; Prasun K Moitra; Peter D'Arpa
Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin.
The Journal of biological chemistry 2002;277(42):40020-6.
2002: Penny A Tavormina; Marie-George Côme; Joanna R Hudson; Yin-Yuan Mo; William T Beck; Gary J Gorbsky
Rapid exchange of mammalian topoisomerase II alpha at kinetochores and chromosome arms in mitosis.
The Journal of cell biology 2002;158(1):23-9.
2002: Yin-Yuan Mo; Yanni Yu; Zhiyuan Shen; William T Beck
Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein.
The Journal of biological chemistry 2002;277(4):2958-64.
2001: William T Beck; Yin-Yuan Mo; Uppoor G Bhat
Cytotoxic signalling by inhibitors of DNA topoisomerase II.
Biochemical Society transactions 2001;29(Pt 6):702-3.
2001: L Cai; K Lim; S Ren; R S Cadena; William T Beck
Synthesis and in vitro antitumor activity of oligonucleotide-tethered and related platinum complexes.
Journal of medicinal chemistry 2001;44(18):2959-65.
2001: SE Morgan; William T Beck
Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.
Molecular pharmacology 2001;59(2):203-11.
2000: Yin-Yuan Mo; Chiayeng Wang; William T Beck
A novel nuclear localization signal in human DNA topoisomerase I.
The Journal of biological chemistry 2000;275(52):41107-13.
2000: SE Morgan; R Kim; P C Wang; Uppoor G Bhat; H Kusumoto; T Lu; William T Beck
Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Oncogene 2000;19(43):5010-9.
2000: Yin-Yuan Mo; P Wang; William T Beck
Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.
Experimental cell research 2000;256(2):480-90.
2000: SE Morgan; R S Cadena; S C Raimondi; William T Beck
Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Molecular pharmacology 2000;57(2):296-307.
1999: T Khélifa; William T Beck
Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells.
Biochemical pharmacology 1999;58(8):1247-57.
1999: Yin-Yuan Mo; William T Beck
Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity.
Experimental cell research 1999;252(1):50-62.
1999: Uppoor G Bhat; Pradip Raychaudhuri; William T Beck
Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(14):7859-64.
1999: T Khélifa; William T Beck
Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease.
Molecular pharmacology 1999;55(3):548-56.
1999: Yin-Yuan Mo; William T Beck
DNA damage signals induction of fas ligand in tumor cells.
Molecular pharmacology 1999;55(2):216-22.
1998: Q Wang; William T Beck
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.
Cancer research 1998;58(24):5762-9.
1998: Yin-Yuan Mo; K A Ameiss; William T Beck
Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein.
BioTechniques 1998;25(6):1052-7.
1998: Robert L Shepard; Mark A Winter; S C Hsaio; H L Pearce; William T Beck; Anne H Dantzig
Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.
Biochemical pharmacology 1998;56(6):719-27.
1998: M Eileen Dolan; Benjamin Frydman; Craig Thompson; Alan M Diamond; B J Garbiras; A R Safa; William T Beck; Laurence J Marton
Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents.
Anti-cancer drugs 1998;9(5):437-48.
1997: Yin-Yuan Mo; Q Wang; William T Beck
Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Cancer research 1997;57(22):5004-8.
1997: William T Beck; T M Grogan
Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins.
Leukemia 1997;11(7):1107-9.
1997: J M Scheltema; J C Romijn; Gert J van Steenbrugge; William T Beck; Fritz H Schröder; G H J Mickisch
Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide.
Journal of cancer research and clinical oncology 1997;123(10):546-54.
1997: William T Beck; T Khélifa; H Kusumoto; Yin-Yuan Mo; Q Rodgers; J S Wolverton; Q Wang
Novel mechanisms of resistance to inhibitors of DNA topoisomerases.
Advances in enzyme regulation 1997;37():17-26.
1997: Johann Hofmann; I Utz; Martin Spitaler; S Hofer; M Rybczynska; William T Beck; D B Herrmann; Hans H Grunicke
Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).
British journal of cancer 1997;76(7):862-9.
1997: Yin-Yuan Mo; William T Beck
Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
Oncology research 1997;9(4):193-204.
1996: William T Beck; Thomas M Grogan; Cheryl L Willman; C Cordon-Cardo; David M Parham; John Frank Kuttesch; M Andreeff; Susan E Bates; CW Berard; J M Boyett; N A Brophy; H J Broxterman; H S Chan; W S Dalton; M Dietel; A T Fojo; R D Gascoyne; D Head; Peter J Houghton; D K Srivastava; M Lehnert; CP Leith; Elisabeth Paietta; Z P Pavelic; R Weinstein
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
Cancer research 1996;56(13):3010-20.
1996: John L. Nitiss; William T Beck
Antitopoisomerase drug action and resistance.
European journal of cancer (Oxford, England : 1990) 1996;32A(6):958-66.
1996: H Kusumoto; Q E Rodgers; F Boege; S C Raimondi; William T Beck
Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Cancer research 1996;56(11):2573-83.
1996: John Frank Kuttesch; David M Parham; X Luo; William H Meyer; L Bowman; DN Shapiro; Alberto S Pappo; William M Crist; William T Beck; Peter J Houghton
P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):886-900.
1996: Erin G Schuetz; William T Beck; John D Schuetz
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Molecular pharmacology 1996;49(2):311-8.
1996: William T Beck
Unanswered questions about multidrug resistance.
Cytotechnology 1996;19(3):177-9.
1995: Uppoor G Bhat; Mark A Winter; H L Pearce; William T Beck
A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
Molecular pharmacology 1995;48(4):682-9.
1995: M Chen; William T Beck
Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Cancer research 1995;55(7):1509-16.
1995: Sharyn D Baker; Randy M Wadkins; Clinton F Stewart; William T Beck; Mary K Danks
Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.
Cytometry 1995;19(2):134-45.
1995: William T Beck
Circumvention of multidrug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact?
Journal of the National Cancer Institute 1995;87(2):73-5.
1995: M Chen; William T Beck
DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Oncology research 1995;7(2):103-11.
1995: S Hashimoto; M K Danks; Satadal Chatterjee; William T Beck; Nathan A Berger
A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
Oncology research 1995;7(1):21-9.
1994: Mary K Danks; J Qiu; Carlo V Catapano; C A Schmidt; William T Beck; Daniel J Fernandes
Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
Biochemical pharmacology 1994;48(9):1785-95.
1994: R Kim; William T Beck
Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Cancer research 1994;54(18):4958-66.
1994: M Kumagai; A Manabe; Elaine Coustan-Smith; R L Blakley; William T Beck; Victor M Santana; Frederick G. Behm; Susana C Raimondi; Dario Campana
Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia.
Leukemia 1994;8(7):1116-23.
1994: William T Beck; Mary K Danks; J S Wolverton; M Chen; B Granzen; R Kim; D P Suttle
Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.
Advances in pharmacology (San Diego, Calif.) 1994;29B():145-69.
1994: William T Beck; R Kim; M Chen
Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S14-8.
1994: M Mariani; L Capolongo; A Suarato; A Bargiotti; Nicola Mongelli; M Grandi; William T Beck
Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.
Investigational new drugs 1994;12(2):93-7.
1993: M Chen; William T Beck
Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Cancer research 1993;53(24):5946-53.
1993: A B Hill; Jeffrey M. Trent; F H Thompson; M K Danks; William T Beck
Loss of tumorigenicity in a methotrexate-resistant human leukemia cell line.
Cancer genetics and cytogenetics 1993;70(1):48-55.
1993: Andrei V Gudkov; C R Zelnick; A R Kazarov; R Thimmapaya; D P Suttle; William T Beck; Igor B Roninson
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(8):3231-5.
1993: Mary K Danks; M R Warmoth; Ellen Friche; B Granzen; B Y Bugg; W G Harker; L A Zwelling; Bernard W Futscher; D P Suttle; William T Beck
Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Cancer research 1993;53(6):1373-9.
1993: William T Beck; Mary K Danks; J S Wolverton; R Kim; M Chen
Drug resistance associated with altered DNA topoisomerase II.
Advances in enzyme regulation 1993;33():113-27.
1993: William T Beck; Mary K Danks; J S Wolverton; B Granzen; M Chen; C A Schmidt; B Y Bugg; Ellen Friche; D P Suttle
Altered DNA topoisomerase II in multidrug resistance.
Cytotechnology 1993;11(2):115-9.
1992: Ellen Friche; Mary K Danks; William T Beck
Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
Cancer research 1992;52(20):5701-6.
1992: William T Beck; John Frank Kuttesch
Neurological symptoms associated with cyclosporin plus doxorubicin.
Lancet 1992;340(8817):496.
1992: J S Wolverton; Mary K Danks; B Granzen; William T Beck
DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Cancer research 1992;52(15):4248-53.
1992: William T Beck; X D Qian
Photoaffinity substrates for P-glycoprotein.
Biochemical pharmacology 1992;43(1):89-93.
1992: B Granzen; D E Graves; B C Baguley; Mary K Danks; William T Beck
Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Oncology research 1992;4(11-12):489-96.
1991: William T Beck
Do anti-P-glycoprotein antibodies have a future in the circumvention of multidrug resistance?
Journal of the National Cancer Institute 1991;83(19):1364-6.
1991: David Kessel; William T Beck; D Kukuruga; V Schulz
Characterization of multidrug resistance by fluorescent dyes.
Cancer research 1991;51(17):4665-70.
1991: B Y Bugg; Mary K Danks; William T Beck; D P Suttle
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(17):7654-8.
1991: Ellen Friche; Mary K Danks; C A Schmidt; William T Beck
Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Cancer research 1991;51(16):4213-8.
1991: William T Beck; Mary K Danks
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Seminars in cancer biology 1991;2(4):235-44.
1991: William T Beck
Modulators of P-glycoprotein-associated multidrug resistance.
Cancer treatment and research 1991;57():151-70.
1990: William T Beck
Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.
Cancer treatment reviews 1990;17 Suppl A():11-20.
1990: X D Qian; William T Beck
Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts.
The Journal of biological chemistry 1990;265(31):18753-6.
1990: Daniel J Fernandes; Mary K Danks; William T Beck
Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Biochemistry 1990;29(17):4235-41.
1990: William T Beck
Multidrug resistance and its circumvention.
European journal of cancer (Oxford, England : 1990) 1990;26(4):513-5.
1990: X D Qian; William T Beck
Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines.
Cancer research 1990;50(4):1132-7.
1990: Kuntebommanahalli N Thimmaiah; Julie K Horton; X D Qian; William T Beck; Janet A Houghton; Peter J Houghton
Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.
Cancer communications 1990;2(7):249-59.
1990: William T Beck
Strategies to circumvent multidrug resistance due to P-glycoprotein or to altered DNA topoisomerase II.
Bulletin du cancer 1990;77(11):1131-41.
1990: H L Pearce; Mark A Winter; William T Beck
Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance.
Advances in enzyme regulation 1990;30():357-73.
1989: Paolo Ubezio; M Limonta; Maurizio D'Incalci; G Damia; G Masera; Giovanni Giudici; J S Wolverton; William T Beck
Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia.
European journal of cancer & clinical oncology 1989;25(12):1895-9.
1989: William T Beck
Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.
Journal of the National Cancer Institute 1989;81(22):1683-5.
1989: C E Cass; Anna Janowska-Wieczorek; M A Lynch; H Sheinin; A A Hindenburg; William T Beck
Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.
Cancer research 1989;49(21):5798-804.
1989: H L Pearce; A R Safa; N J Bach; Mark A Winter; M C Cirtain; William T Beck
Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(13):5128-32.
1989: J S Wolverton; Mary K Danks; C A Schmidt; William T Beck
Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Cancer research 1989;49(9):2422-6.
1989: Mary K Danks; C A Schmidt; D A Deneka; William T Beck
Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
Cancer communications 1989;1(2):101-9.
1988: Mary K Danks; C A Schmidt; M C Cirtain; D P Suttle; William T Beck
Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
Biochemistry 1988;27(24):8861-9.
1988: William T Beck; M C Cirtain; C J Glover; R L Felsted; A R Safa
Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine.
Biochemical and biophysical research communications 1988;153(3):959-66.
1988: J M Zamora; H L Pearce; William T Beck
Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
Molecular pharmacology 1988;33(4):454-62.
1988: S C Lee; Carol Deutsch; William T Beck
Comparison of ion channels in multidrug-resistant and -sensitive human leukemic cells.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(6):2019-23.
1988: A B Hill; William T Beck; Jeffrey M. Trent
Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Cancer research 1988;48(2):393-8.
1987: William T Beck; M C Cirtain; Mary K Danks; R L Felsted; A R Safa; J S Wolverton; D P Suttle; Jeffrey M. Trent
Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Cancer research 1987;47(20):5455-60.
1987: William T Beck
The cell biology of multiple drug resistance.
Biochemical pharmacology 1987;36(18):2879-87.
1987: Michael J Kelner; Trevor C McMorris; William T Beck; J M Zamora; R Taetle
Preclinical evaluation of illudins as anticancer agents.
Cancer research 1987;47(12):3186-9.
1987: M K Danks; J C Yalowich; William T Beck
Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
Cancer research 1987;47(5):1297-301.
1986: J M Zamora; William T Beck
Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells.
Biochemical pharmacology 1986;35(23):4303-10.
1986: William T Beck; M C Cirtain; R A Ashmun; J Mirro
Differentiation and the multiple drug resistance phenotype in human leukemic cells.
Cancer research 1986;46(9):4571-5.
1986: William T Beck; M C Cirtain; A T Look; R A Ashmun
Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Cancer research 1986;46(2):778-84.
1986: William T Beck; Mary K Danks; M C Cirtain; J N van Heiningen
Cross-resistance patterns and antigen expression in Vinca alkaloid- and other multiple drug-resistant human leukemic cell lines.
Progress in clinical and biological research 1986;223():3-10.
1985: Mary K Danks; D W Metzger; R A Ashmun; William T Beck
Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells.
Cancer research 1985;45(7):3220-4.
1984: V Conter; William T Beck
Acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine.
Cancer treatment reports 1984;68(6):831-9.
1984: William T Beck
Cellular pharmacology of Vinca alkaloid resistance and its circumvention.
Advances in enzyme regulation 1984;22():207-27.
1983: William T Beck; M C Cirtain; J L Lefko
Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Molecular pharmacology 1983;24(3):485-92.
1983: William T Beck
Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts.
Cancer treatment reports 1983;67(10):875-82.
1983: V Conter; William T Beck
Impairment by ruthenium red of anticancer drug cytotoxicity in CCRF-CEM cells.
Biochemical pharmacology 1983;32(4):723-6.
1983: J R Katze; William T Beck; C S Cheng; J A McCloskey
Why is tumor tRNA hypomodified with respect to Q nucleoside?
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1983;84():146-59.
1982: William T Beck; M L Dedmon; M A Ouellette
Biochemical basis for impaired drug metabolism in tumor-bearing rats. Evidence for altered regulation of hepatic microsomal hemeprotein synthesis.
Biochemical pharmacology 1982;31(8):1535-43.
1982: William T Beck; M C Cirtain
Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase.
Cancer research 1982;42(1):184-9.
1980: J R Katze; William T Beck
Administration of queuine to mice relieves modified nucleoside queuosine deficiency in Ehrlich ascites tumor tRNA.
Biochemical and biophysical research communications 1980;96(1):313-9.
1980: William T Beck
Increase by vinblastine of oxidized glutathione in cultured mammalian cells.
Biochemical pharmacology 1980;29(17):2333-7.
1979: William T Beck; T J Mueller; L R Tanzer
Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.
Cancer research 1979;39(6 Pt 1):2070-6.
1977: J T Chou; William T Beck; T Khwaja; K Mayer; E Lien
Synthesis and anticancer activity of novel cyclic N-hydroxyureas.
Journal of pharmaceutical sciences 1977;66(11):1556-61.
1975: William T Beck; H G Mandel; S Fabro
Physiological disposition of pentobarbital in tumor-bearing mice.
Cancer research 1975;35(5):1333-40.
1973: William T Beck; R A Bellantone; E S Canellakis
Puromycin stimulation of rat liver ornithine decarboxylase activity.
Nature 1973;241(5387):275-7.
1972: William T Beck; R A Bellantone; E S Canellakis
The in vivo stimulation of rat liver ornithine decarboxylase activity by dibutyryl cyclic adenosine 3',5'-monophosphate, theophylline and dexamethasone.
Biochemical and biophysical research communications 1972;48(6):1649-55.